Open-Label Surufatinib in European Patients With NET

ABSTRACT: This is a Phase 2, open-label, multi-centre study of surufatinib in patients with low to intermediate grade (Grade 1 or Grade 2), well-differentiated neuroendocrine tumours (NETs).

DISEASE(S): Neuroendocrine Tumors,Neuroendocrine Tumours,Neuroendocrine Tumour,Small Intestinal Net,Lung Neoplasms,Neoplasms,Neuroendocrine Tumour Of The Lung

PROVIDER: 2353926 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR